Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Smith

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Human Vaccines|October 3, 2006
Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old childrenScott A Halperin, Joanne M Langley, Teresa M Hesley, et al.
HIV Clinical Trials|February 7, 2012
High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adultsCurtis Cooper, Marina Klein, Sharon Walmsley, et al.
The New Zealand Medical Journal|May 17, 2019
Developing New Zealand's medical workforce: realising the potential of longitudinal career trackingPhillippa Poole, Tim J Wilkinson, Warwick Bagg, et al.
Vaccine|December 23, 2023
An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) studyJoanne M Langley, Soren Gantt, Scott A Halperin, et al.
Clinical Immunology (Orlando, Fla.)|August 14, 2002
Increased microchimeric CD4+ T lymphocytes in peripheral blood from women with systemic sclerosisCarol M Artlett, Lori A Cox, Ronald C Ramos, et al.
The Pediatric Infectious Disease Journal|April 18, 2020
Adverse Events Following Immunization Among Children With Epilepsy: A Self-Controlled Case SeriesKarina A Top, Christiaan H Righolt, Steven Hawken, et al.
Human Vaccines & Immunotherapeutics|April 11, 2013
Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccineScott A Halperin, Brian J Ward, Marc Dionne, et al.
Vaccine|October 4, 2005
Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adultsScott A Halperin, Simon Dobson, Shelly McNeil, et al.
Vaccine|March 16, 2021
Vaccine coverage among children with epilepsy in two Canadian provinces: A Canadian immunization research network studyChristiaan H Righolt, Gurpreet Pabla, Jessy Donelle, et al.
Journal of Oncology Practice|February 18, 2018
Characterizing Potentially Preventable Cancer- and Chronic Disease-Related Emergency Department Use in the Year After Treatment Initiation: A Regional StudyLaura Panattoni, Catherine Fedorenko, Mikael Anne Greenwood-Hickman, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Human Vaccines|October 3, 2006
Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old childrenScott A Halperin, Joanne M Langley, Teresa M Hesley, et al.
HIV Clinical Trials|February 7, 2012
High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adultsCurtis Cooper, Marina Klein, Sharon Walmsley, et al.
The New Zealand Medical Journal|May 17, 2019
Developing New Zealand's medical workforce: realising the potential of longitudinal career trackingPhillippa Poole, Tim J Wilkinson, Warwick Bagg, et al.
Vaccine|December 23, 2023
An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) studyJoanne M Langley, Soren Gantt, Scott A Halperin, et al.
Clinical Immunology (Orlando, Fla.)|August 14, 2002
Increased microchimeric CD4+ T lymphocytes in peripheral blood from women with systemic sclerosisCarol M Artlett, Lori A Cox, Ronald C Ramos, et al.
The Pediatric Infectious Disease Journal|April 18, 2020
Adverse Events Following Immunization Among Children With Epilepsy: A Self-Controlled Case SeriesKarina A Top, Christiaan H Righolt, Steven Hawken, et al.
Human Vaccines & Immunotherapeutics|April 11, 2013
Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccineScott A Halperin, Brian J Ward, Marc Dionne, et al.
Vaccine|October 4, 2005
Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adultsScott A Halperin, Simon Dobson, Shelly McNeil, et al.
Vaccine|March 16, 2021
Vaccine coverage among children with epilepsy in two Canadian provinces: A Canadian immunization research network studyChristiaan H Righolt, Gurpreet Pabla, Jessy Donelle, et al.
Journal of Oncology Practice|February 18, 2018
Characterizing Potentially Preventable Cancer- and Chronic Disease-Related Emergency Department Use in the Year After Treatment Initiation: A Regional StudyLaura Panattoni, Catherine Fedorenko, Mikael Anne Greenwood-Hickman, et al.
Pageof 8